I've stopped flinching at big scary multipliers. Spend enough years watching a niche go from nothing to everything overnight, and a headline that screams "310-fold" reads differently to me than it probably does to you.

That's the number attached to a new report on GLP-1 prescribing in young children with obesity — a jump from The American Journal of Managed Care that's rightfully making people sit up. Rare to common, seemingly overnight. And I get why that number alone feels like a klaxon.

But I've lived inside numbers like that before, just in a different arena. Back in 2010, while everyone else was busy discovering WordPress, I was running five hundred hand-coded, RSS-fed autoblogs — and when Google dropped an algorithm update that wiped out half the internet's shortcuts, my sites coughed, stumbled, and recovered. The lesson wasn't "big number, big danger." It was "look at what's underneath the number before you decide what it means."

That instinct is basically my whole career. I sold my first car on eBay using what was, at the time, a genuinely weird idea — a photo-and-video listing, when nobody did that. It looked radical for about six months, then it became the standard everyone expected. Rare-to-common jumps aren't always alarm bells; sometimes they're just the moment a practice catches up to real demand, or real evidence, or real access finally lining up.

That doesn't mean this particular jump isn't worth real scrutiny — it absolutely is, especially with kids involved and long-term data still young. I'm not a clinician, and I'm not going to pretend a guy who cut his teeth coding in Notepad has medical authority here. What I do have is decades of watching how fast adoption curves bend once a tool moves from "fringe experiment" to "standard toolkit," and how often the headline number outruns the nuance underneath it.

What actually earns my attention isn't the multiplier — it's who's tracking it, how transparently, and whether the systems reporting it are built to catch the trend early or just react to it after the fact. That's the same instinct that pushed me to build tools that watch data quietly in the background so I'm not the one white-knuckling a dashboard at midnight, waiting for a spike to explain itself.

So here's my honest gut-check: big jumps deserve curiosity before conclusions. Ask what changed in the pipeline before you decide what changed in the risk.

Next time, I want to dig into how we tell the difference between a trend that's scaling responsibly and one that's just scaling loudly — stick around, that one's worth the coffee.